» Articles » PMID: 16550045

Advances in the Diagnosis, Evaluation and Management of Cholangiocarcinoma

Overview
Specialty Gastroenterology
Date 2006 Mar 22
PMID 16550045
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: Cholangiocarcinoma is an enigmatic malignancy of the biliary tract that has recently been shown to be increasing in incidence globally. There has been recent progress in identifying potential risk factors for the tumor, and in the use of emerging technologies for diagnosis and palliative treatment.

Recent Findings: Hepatitis B and C, cirrhosis and alcohol have been described as risk factors for cholangiocarcinoma. A morphology-based classification for cholangiocarcinoma is proposed that will facilitate future descriptive epidemiology, diagnosis and comparative therapeutic studies. Diagnosis may be improved by new approaches to enhance the diagnostic yield and utility of biliary cytology. The role of new imaging approaches such as positron emission tomography scanning, endoscopic ultrasound or optical coherence tomography for diagnosis are being examined and defined. Long-term results for transplantation protocols for curative intent in non-resectable localized disease have been described. Photodynamic therapy looks extremely promising for adjunct therapy of intrahepatic mass lesions.

Summary: Recent advances in the epidemiology, classification, diagnosis and therapy of cholangiocarcinoma are expected to enhance the evaluation and management of patients with this devastating malignancy.

Citing Articles

A novel five-lncRNA signature panel improves high-risk survival prediction in patients with cholangiocarcinoma.

Xie X, Wang Y, Zhang S, Li J, Yu Z, Ding X Aging (Albany NY). 2021; 13(2):2959-2981.

PMID: 33472169 PMC: 7880389. DOI: 10.18632/aging.202446.


Next-generation sequencing and personalized genomic medicine in hepatobiliary malignancies.

Loaiza-Bonilla A, Furth E, Morrissette J Hepat Oncol. 2018; 2(4):359-370.

PMID: 30191018 PMC: 6095428. DOI: 10.2217/hep.15.20.


Anticancer activities of epigallocatechin-3-gallate against cholangiocarcinoma cells.

Kwak T, Park S, Kim H, Jeong Y, Kang D Onco Targets Ther. 2017; 10():137-144.

PMID: 28053547 PMC: 5189709. DOI: 10.2147/OTT.S112364.


Cholangiocarcinoma: Present Status and Molecular Aspects of Diagnosis.

Liu X, Tang K, Sui L, Xu G Oncol Res. 2015; 22(4):177-183.

PMID: 26351206 PMC: 7838449. DOI: 10.3727/096504015X14343704124386.


Anticancer activity of streptochlorin, a novel antineoplastic agent, in cholangiocarcinoma.

Kwak T, Shin H, Jeong Y, Han M, Oh S, Kim H Drug Des Devel Ther. 2015; 9:2201-14.

PMID: 25931814 PMC: 4404940. DOI: 10.2147/DDDT.S80205.